Search This Blog

Thursday, June 18, 2026

Denali to sell FDA Rare Pediatric Disease Priority Review Voucher

 

Denali Therapeutics enters definitive agreement to sell FDA Rare Pediatric Disease Priority Review Voucher for $195 million

  • Proceeds are intended to bolster funding for Denali's TransportVehicle-enabled clinical pipeline.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)